{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:39:13Z","timestamp":1792931953720,"version":"4.5.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00744-w","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:55:15Z","timestamp":1769522115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation"],"prefix":"10.1186","volume":"15","author":[{"given":"Farshad","family":"Heydari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Naghinezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"5","key":"744_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM, Acute Myeloid L. 2025 update on Diagnosis, Risk-Stratification, and management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"key":"744_CR2","doi-asserted-by":"crossref","unstructured":"Goel P, Aryal S, Franceski AM, Kuznetsova V, Costa AFO, Luca F et al. The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF\u03baB signaling. Blood. 2025.","DOI":"10.1182\/blood.2024028199"},{"issue":"12","key":"744_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1182\/blood.2024024010","volume":"145","author":"GJ Roboz","year":"2025","unstructured":"Roboz GJ, Canaani J. How I use maintenance therapy in acute myeloid leukemia. Blood. 2025;145(12):1273\u201381.","journal-title":"Blood"},{"issue":"Suppl 2","key":"744_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.27583","volume":"100","author":"H Goulart","year":"2025","unstructured":"Goulart H, Wei AH, Kadia TM. Maintenance therapy in AML: what is the future potential? Am J Hematol. 2025;100(Suppl 2):38\u201349.","journal-title":"Am J Hematol"},{"issue":"1","key":"744_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s10238-025-01795-9","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Shafiei FS, Taghinejad Z, Maleknia M, Noormohamadi H, Raoufi A, et al. The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies. Clin Exp Med. 2025;25(1):240.","journal-title":"Clin Exp Med"},{"key":"744_CR6","doi-asserted-by":"publisher","first-page":"1627161","DOI":"10.3389\/fimmu.2025.1627161","volume":"16","author":"M Liu","year":"2025","unstructured":"Liu M, Yang M, Qi Y, Ma Y, Guo Q, Guo L, et al. Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target. Front Immunol. 2025;16:1627161.","journal-title":"Front Immunol"},{"issue":"1","key":"744_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Noormohamadi H, Shafiei FS, Taghinejad Z, Maleknia M, Raoufi A, et al. Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin Exp Med. 2025;25(1):215.","journal-title":"Clin Exp Med"},{"key":"744_CR8","doi-asserted-by":"crossref","unstructured":"Abbasi-Shahkouh A, Rashidan K, Azadmehr A, Atashi A. Exploring the role of neutrophil extracellular traps in leukemia: a comprehensive review. Leuk Lymphoma. 2025:1\u201311.","DOI":"10.1080\/10428194.2025.2547990"},{"issue":"6","key":"744_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41565-023-01374-7","volume":"18","author":"Z Luo","year":"2023","unstructured":"Luo Z, Lu Y, Shi Y, Jiang M, Shan X, Li X, et al. Neutrophil hitchhiking for drug delivery to the bone marrow. Nat Nanotechnol. 2023;18(6):647\u201356.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"744_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12645-025-00340-3","volume":"16","author":"J Naghinezhad","year":"2025","unstructured":"Naghinezhad J, Moradpanah S, Khodakarim N, Hamblin MR, Rezaeeyan H. Nanodrug-based modulation of platelet\u2013leukocyte interactions in ovarian cancer: a new frontier in targeted therapy. Cancer Nanotechnol. 2025;16(1):37.","journal-title":"Cancer Nanotechnol"},{"issue":"1","key":"744_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s12672-025-02526-y","volume":"16","author":"N Lu","year":"2025","unstructured":"Lu N, Liu L, Cao Y, Zhang R, Zhai W, Chen X, et al. Efficacy and safety of Mitoxantrone hydrochloride liposome-containing regimens in treating refractory\/relapsed acute myeloid leukemia. Discover Oncol. 2025;16(1):727.","journal-title":"Discover Oncol"},{"issue":"1","key":"744_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, Nouri S, Hussen A, Bayani A, Khaksari MN, Soleimani Samarkhazan H. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Exp Med. 2025;25(1):166.","journal-title":"Clin Exp Med"},{"issue":"6","key":"744_CR13","doi-asserted-by":"publisher","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","volume":"7","author":"S Turkalj","year":"2023","unstructured":"Turkalj S, Radtke FA, Vyas P. An overview of targeted therapies in acute myeloid leukemia. Hemasphere. 2023;7(6):e914.","journal-title":"Hemasphere"},{"issue":"12","key":"744_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1182\/blood.2024024009","volume":"145","author":"AH Wei","year":"2025","unstructured":"Wei AH, Loo S, Daver N. How I treat patients with AML using Azacitidine and venetoclax. Blood. 2025;145(12):1237\u201350.","journal-title":"Blood"},{"issue":"20","key":"744_CR15","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.3390\/jcm12206429","volume":"12","author":"C Negotei","year":"2023","unstructured":"Negotei C, Colita A, Mitu I, Lupu AR, Lapadat M-E, Popovici CE, et al. A review of FLT3 kinase inhibitors in AML. J Clin Med. 2023;12(20):6429.","journal-title":"J Clin Med"},{"issue":"5","key":"744_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","volume":"38","author":"H Fruchtman","year":"2024","unstructured":"Fruchtman H, Avigan ZM, Waksal JA, Brennan N, Mascarenhas JO. Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia. Leukemia. 2024;38(5):927\u201335.","journal-title":"Leukemia"},{"issue":"2","key":"744_CR17","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/hematolrep16020024","volume":"16","author":"A Candoni","year":"2024","unstructured":"Candoni A, Coppola G. A 2024 update on Menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia. Hematol Rep. 2024;16(2):244\u201354.","journal-title":"Hematol Rep"},{"issue":"6","key":"744_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/cancers16061091","volume":"16","author":"S Garciaz","year":"2024","unstructured":"Garciaz S, Hospital M-A, Collette Y, Vey N. Venetoclax resistance in acute myeloid leukemia. Cancers. 2024;16(6):1091.","journal-title":"Cancers"},{"issue":"1","key":"744_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14(1):163.","journal-title":"Blood Cancer J"},{"issue":"9","key":"744_CR20","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/cancers17091586","volume":"17","author":"T Chatzilygeroudi","year":"2025","unstructured":"Chatzilygeroudi T, Karantanos T, Pappa V. Unraveling venetoclax resistance: navigating the future of HMA\/venetoclax-refractory AML in the molecular era. Cancers. 2025;17(9):1586.","journal-title":"Cancers"},{"issue":"6","key":"744_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41419-024-06810-7","volume":"15","author":"GO Nwosu","year":"2024","unstructured":"Nwosu GO, Ross DM, Powell JA, Pitson SM. Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death Dis. 2024;15(6):413.","journal-title":"Cell Death Dis"},{"key":"744_CR22","doi-asserted-by":"publisher","first-page":"104424","DOI":"10.1016\/j.critrevonc.2024.104424","volume":"201","author":"M Ruglioni","year":"2024","unstructured":"Ruglioni M, Crucitta S, Luculli GI, Tancredi G, Del Giudice ML, Mechelli S, et al. Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy. Crit Rev Oncol\/Hematol. 2024;201:104424.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"744_CR23","first-page":"1126","volume":"110","author":"MA Sobas","year":"2024","unstructured":"Sobas MA, Turki AT, Ramiro AV, Hern\u00e1ndez-S\u00e1nchez A, Elicegui JM, Gonz\u00e1lez T, et al. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY alliance. Haematologica. 2024;110(5):1126.","journal-title":"Haematologica"},{"issue":"13","key":"744_CR24","doi-asserted-by":"publisher","first-page":"e35960","DOI":"10.1002\/cncr.35960","volume":"131","author":"M Boyiadzis","year":"2025","unstructured":"Boyiadzis M, Wei AH, Paiva B, Freeman SD, Kaspers G, Chyla B, et al. Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): perspectives from the MRD partnership and alliance in AML clinical treatment consortium. Cancer. 2025;131(13):e35960.","journal-title":"Cancer"},{"key":"744_CR25","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"issue":"6","key":"744_CR26","first-page":"1150","volume":"114","author":"SW Lane","year":"2009","unstructured":"Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood J Am Soc Hematol. 2009;114(6):1150\u20137.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"744_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/ijms24010563","volume":"24","author":"KA Skelding","year":"2022","unstructured":"Skelding KA, Barry DL, Theron DZ, Lincz LF. Bone marrow microenvironment as a source of new drug targets for the treatment of acute myeloid leukaemia. Int J Mol Sci. 2022;24(1):563.","journal-title":"Int J Mol Sci"},{"key":"744_CR28","doi-asserted-by":"crossref","unstructured":"Pan Q, Mahato RI. Recent advances in drug delivery and treatment strategies for acute myeloid leukemia. Int J Pharm. 2025:126078.","DOI":"10.1016\/j.ijpharm.2025.126078"},{"issue":"6","key":"744_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41565-023-01373-8","volume":"18","author":"N Gong","year":"2023","unstructured":"Gong N, Mitchell MJ. Rerouting nanoparticles to bone marrow via neutrophil hitchhiking. Nat Nanotechnol. 2023;18(6):548\u20139.","journal-title":"Nat Nanotechnol"},{"key":"744_CR30","doi-asserted-by":"publisher","first-page":"1026386","DOI":"10.3389\/fphar.2022.1026386","volume":"13","author":"Z Dai","year":"2022","unstructured":"Dai Z, Zhao T, Song N, Pan K, Yang Y, Zhu X, et al. Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects. Front Pharmacol. 2022;13:1026386.","journal-title":"Front Pharmacol"},{"issue":"42","key":"744_CR31","doi-asserted-by":"publisher","first-page":"2403409","DOI":"10.1002\/smll.202403409","volume":"20","author":"X Wu","year":"2024","unstructured":"Wu X, Wang F, Yang X, Gong Y, Niu T, Chu B, et al. Advances in drug delivery systems for the treatment of acute myeloid leukemia. Small. 2024;20(42):2403409.","journal-title":"Small"},{"issue":"1","key":"744_CR32","doi-asserted-by":"publisher","first-page":"2000018","DOI":"10.1002\/sstr.202000018","volume":"1","author":"S Wang","year":"2020","unstructured":"Wang S, Duan Y, Zhang Q, Komarla A, Gong H, Gao W, et al. Drug targeting via platelet Membrane\u2013Coated nanoparticles. Small Struct. 2020;1(1):2000018.","journal-title":"Small Struct"},{"key":"744_CR33","doi-asserted-by":"publisher","first-page":"983874","DOI":"10.3389\/fonc.2022.983874","volume":"12","author":"X Li","year":"2022","unstructured":"Li X, Hu L, Tan C, Wang X, Ran Q, Chen L, et al. Platelet-promoting drug delivery efficiency for Inhibition of tumor growth, metastasis, and recurrence. Front Oncol. 2022;12:983874.","journal-title":"Front Oncol"},{"key":"744_CR34","doi-asserted-by":"crossref","unstructured":"Song B, Na Y-G, Kim BJ, Jin M, Song YH, Kim D-E et al. Platelet Membrane-Coated Poly (Lactic-Co-Glycolic Acid) nanoparticles as a targeting drug delivery system for Multidrug-Resistant breast cancer. Int J Nanomed. 2025:8529\u201345.","DOI":"10.2147\/IJN.S517753"},{"key":"744_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2022.01.004","volume":"172","author":"H Han","year":"2022","unstructured":"Han H, Bartolo R, Li J, Shahbazi M-A, Santos HA. Biomimetic platelet membrane-coated nanoparticles for targeted therapy. Eur J Pharm Biopharm. 2022;172:1\u201315.","journal-title":"Eur J Pharm Biopharm"},{"issue":"16","key":"744_CR36","doi-asserted-by":"publisher","first-page":"15542","DOI":"10.1021\/acsnano.3c02013","volume":"17","author":"Y Su","year":"2023","unstructured":"Su Y, Gao J, Dong X, Wheeler KA, Wang Z. Neutrophil-mediated delivery of nanocrystal drugs via photoinduced inflammation enhances cancer therapy. ACS Nano. 2023;17(16):15542\u201355.","journal-title":"ACS Nano"},{"issue":"4","key":"744_CR37","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.3390\/ijms23042223","volume":"23","author":"N-H Lee","year":"2022","unstructured":"Lee N-H, You S, Taghizadeh A, Taghizadeh M, Kim HS. Cell membrane-cloaked nanotherapeutics for targeted drug delivery. Int J Mol Sci. 2022;23(4):2223.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"744_CR38","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1080\/10717544.2022.2117434","volume":"29","author":"Z Fang","year":"2022","unstructured":"Fang Z, Fang J, Gao C, Gao R, Lin P, Yu W. Recent trends in platelet membrane-cloaked nanoparticles for application of inflammatory diseases. Drug Delivery. 2022;29(1):2805\u201314.","journal-title":"Drug Delivery"},{"key":"744_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fphar.2020.00024","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Liu J, Sun M, Wang J, Wang C, Sun Y. Cell membrane-camouflaged nanocarriers for cancer diagnostic and therapeutic. Front Pharmacol. 2020;11:24.","journal-title":"Front Pharmacol"},{"key":"744_CR40","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bioactmat.2024.01.022","volume":"35","author":"S Yuan","year":"2024","unstructured":"Yuan S, Hu Q. Convergence of nanomedicine and neutrophils for drug delivery. Bioactive Mater. 2024;35:150\u201366.","journal-title":"Bioactive Mater"},{"issue":"5","key":"744_CR41","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/17425247.2023.2217378","volume":"20","author":"D Cacic","year":"2023","unstructured":"Cacic D, Hervig T, Reikvam H. Platelets for advanced drug delivery in cancer. Expert Opin Drug Deliv. 2023;20(5):673\u201388.","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"744_CR42","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1038\/s41588-024-01999-x","volume":"56","author":"A-M Lepp\u00e4","year":"2024","unstructured":"Lepp\u00e4 A-M, Grimes K, Jeong H, Huang FY, Andrades A, Waclawiczek A, et al. Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype. Nat Genet. 2024;56(12):2790\u2013803.","journal-title":"Nat Genet"},{"issue":"1","key":"744_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-cancerbio-062822-025055","volume":"8","author":"MF Jones","year":"2024","unstructured":"Jones MF, Smith CC. Mechanisms of resistance to targeted therapies in AML. Annual Rev Cancer Biology. 2024;8(1):81\u201396.","journal-title":"Annual Rev Cancer Biology"},{"issue":"1","key":"744_CR44","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41467-025-58370-9","volume":"16","author":"S Takao","year":"2025","unstructured":"Takao S, Morell V, Uni M, Slavit A, Rha S, Cheng S, et al. Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance. Nat Commun. 2025;16(1):3196.","journal-title":"Nat Commun"},{"issue":"1","key":"744_CR45","doi-asserted-by":"publisher","first-page":"9402","DOI":"10.1038\/s41467-024-53535-4","volume":"15","author":"R Wegmann","year":"2024","unstructured":"Wegmann R, Bonilla X, Casanova R, Chevrier S, Coelho R, Esposito C, et al. Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia. Nat Commun. 2024;15(1):9402.","journal-title":"Nat Commun"},{"issue":"4","key":"744_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.21037\/atm-23-1824","volume":"12","author":"AP Urs","year":"2024","unstructured":"Urs AP, Goda C, Kulkarni R. Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression. Annals Translational Med. 2024;12(4):63.","journal-title":"Annals Translational Med"},{"issue":"2","key":"744_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108(2):353.","journal-title":"Haematologica"},{"issue":"1","key":"744_CR48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41420-022-01193-0","volume":"8","author":"Y Chen","year":"2022","unstructured":"Chen Y, Li J, Xu L, G\u0103man M-A, Zou Z. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: from biology to therapeutic targeting. Cell Death Discovery. 2022;8(1):397.","journal-title":"Cell Death Discovery"},{"key":"744_CR49","doi-asserted-by":"crossref","unstructured":"Dunn WG, McLoughlin MA, Vassiliou GS. Clonal hematopoiesis and hematological malignancy. J Clin Investig. 2024;134(19).","DOI":"10.1172\/JCI180065"},{"key":"744_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fonc.2016.00187","volume":"6","author":"H Sato","year":"2016","unstructured":"Sato H, Wheat JC, Steidl U, Ito K. DNMT3A and TET2 in the pre-leukemic phase of hematopoietic disorders. Front Oncol. 2016;6:187.","journal-title":"Front Oncol"},{"key":"744_CR51","doi-asserted-by":"publisher","first-page":"e93019","DOI":"10.7554\/eLife.93019","volume":"13","author":"K Nuno","year":"2024","unstructured":"Nuno K, Azizi A, K\u00f6hnke T, Lareau C, Ediriwickrema A, Corces MR, et al. Convergent epigenetic evolution drives relapse in acute myeloid leukemia. Elife. 2024;13:e93019.","journal-title":"Elife"},{"issue":"12","key":"744_CR52","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/biom13121701","volume":"13","author":"S Giallongo","year":"2023","unstructured":"Giallongo S, Duminuco A, Dulcamare I, Zuppelli T, La Spina E, Scandura G, et al. Engagement of mesenchymal stromal cells in the remodeling of the bone marrow microenvironment in hematological cancers. Biomolecules. 2023;13(12):1701.","journal-title":"Biomolecules"},{"issue":"1","key":"744_CR53","doi-asserted-by":"publisher","first-page":"10832","DOI":"10.1038\/s41467-024-55051-x","volume":"15","author":"T Xing","year":"2024","unstructured":"Xing T, Hu L-J, Zhao H-Y, Li C-Y, Wang Z-K, Shen M-Z, et al. Bone marrow endothelial progenitor cells remodelling facilitates normal hematopoiesis during acute myeloid leukemia complete remission. Nat Commun. 2024;15(1):10832.","journal-title":"Nat Commun"},{"key":"744_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fonc.2020.00155","volume":"10","author":"Y Tabe","year":"2020","unstructured":"Tabe Y, Konopleva M, Andreeff M. Fatty acid metabolism, bone marrow adipocytes, and AML. Front Oncol. 2020;10:155.","journal-title":"Front Oncol"},{"key":"744_CR55","doi-asserted-by":"crossref","unstructured":"Dembitz V, James SC, Gallipoli P. Targeting lipid metabolism in acute myeloid leukemia: biological insights and therapeutic opportunities: ACUTE MYELOID LEUKEMIA. Leukemia. 2025:1\u201310.","DOI":"10.1038\/s41375-025-02645-z"},{"key":"744_CR56","doi-asserted-by":"crossref","unstructured":"Gui G, Bingham MA, Herzog JR, Wong-Rolle A, Dillon LW, Goswami M et al. Single Cell Spatial Transcriptomics Reveals Immunotherapy-Driven Bone Marrow Niche Remodeling in AML. bioRxiv. 2025.","DOI":"10.1101\/2025.01.24.634753"},{"issue":"2","key":"744_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41375-024-02480-8","volume":"39","author":"RA Cooper","year":"2025","unstructured":"Cooper RA, Thomas E, Sozanska AM, Pescia C, Royston DJ. Spatial transcriptomic approaches for characterising the bone marrow landscape: pitfalls and potential. Leukemia. 2025;39(2):291\u20135.","journal-title":"Leukemia"},{"key":"744_CR58","doi-asserted-by":"crossref","unstructured":"Lisi-Vega LE, Pievani A, Garc\u00eda-Fern\u00e1ndez M, Forte D, Williams TL, Serafini M et al. Bone marrow mesenchymal stromal cells support translation in refractory acute myeloid leukemia. Cell Rep. 2025;44(1).","DOI":"10.1016\/j.celrep.2024.115151"},{"issue":"8","key":"744_CR59","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3324\/haematol.2017.183418","volume":"103","author":"GJ Roboz","year":"2018","unstructured":"Roboz GJ, Ritchie EK, Dault Y, Lam L, Marshall DC, Cruz NM, et al. Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica. 2018;103(8):1308\u201316.","journal-title":"Haematologica"},{"issue":"8","key":"744_CR60","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1182\/blood.2021010721","volume":"139","author":"DJ DeAngelo","year":"2022","unstructured":"DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, et al. Phase 1\/2 study of Uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022;139(8):1135\u201346.","journal-title":"Blood"},{"issue":"5","key":"744_CR61","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1208\/s12248-017-0114-4","volume":"19","author":"AG Zestos","year":"2017","unstructured":"Zestos AG, Kennedy RT. Microdialysis coupled with LC-MS\/MS for in vivo neurochemical monitoring. Aaps J. 2017;19(5):1284\u201393.","journal-title":"Aaps J"},{"issue":"2","key":"744_CR62","doi-asserted-by":"publisher","first-page":"e22169","DOI":"10.1002\/ddr.22169","volume":"85","author":"M Wang","year":"2024","unstructured":"Wang M, Jin Z, Huang H, Cheng X, Zhang Q, Tang Y, et al. Neutrophil hitchhiking: riding the drug delivery wave to treat diseases. Drug Dev Res. 2024;85(2):e22169.","journal-title":"Drug Dev Res"},{"key":"744_CR63","doi-asserted-by":"crossref","unstructured":"Reinhardt C, Ochsenbein AF. Immune checkpoints regulate acute myeloid leukemia stem cells. Leukemia. 2025:1\u201317.","DOI":"10.1038\/s41375-025-02566-x"},{"issue":"1","key":"744_CR64","doi-asserted-by":"publisher","first-page":"ltac019","DOI":"10.1093\/immadv\/ltac019","volume":"2","author":"S Schwartz","year":"2022","unstructured":"Schwartz S, Patel N, Longmire T, Jayaraman P, Jiang X, Lu H, et al. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor. Immunotherapy Adv. 2022;2(1):ltac019.","journal-title":"Immunotherapy Adv"},{"issue":"3","key":"744_CR65","doi-asserted-by":"publisher","first-page":"e70051","DOI":"10.1002\/jha2.70051","volume":"6","author":"GN Mannis","year":"2025","unstructured":"Mannis GN, Abboud CN, Daver NG, Murthy GSG, Wang ES, Bradley TJ, et al. Phase 2 Multi-Arm study of Magrolimab combinations in patients with acute myeloid leukaemia. EJHaem. 2025;6(3):e70051.","journal-title":"EJHaem"},{"key":"744_CR66","doi-asserted-by":"crossref","unstructured":"Zeidner JF, Sallman DA, R\u00e9cher C, Daver NG, Leung AY, Hiwase DK et al. Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood Journal. 2025:blood. 2024027408.","DOI":"10.1182\/blood.2024027408"},{"key":"744_CR67","doi-asserted-by":"publisher","first-page":"1000996","DOI":"10.3389\/fimmu.2022.1000996","volume":"13","author":"M Luciano","year":"2022","unstructured":"Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol. 2022;13:1000996.","journal-title":"Front Immunol"},{"key":"744_CR68","doi-asserted-by":"publisher","first-page":"1627161","DOI":"10.3389\/fimmu.2025.1627161","volume":"16","author":"M Liu","year":"2025","unstructured":"Liu M, Yang M, Ma Y, Guo Q, Guo L, Liu C, et al. Immunosuppressive cells in acute myeloid leukemia: mechanisms and therapeutic target. Front Immunol. 2025;16:1627161.","journal-title":"Front Immunol"},{"issue":"5","key":"744_CR69","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"744_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3324\/haematol.2022.280765","volume":"108","author":"M Othus","year":"2022","unstructured":"Othus M, Garcia-Manero G, Godwin JE, Weick JK, Appelbaum FR, Erba HP, et al. Improved outcomes with 7\u2009+\u20093 induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data. Haematologica. 2022;108(1):42.","journal-title":"Haematologica"},{"issue":"10","key":"744_CR71","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3324\/haematol.2022.281045","volume":"107","author":"A Tefferi","year":"2022","unstructured":"Tefferi A, Gangat N, Shah M, Alkhateeb H, Patnaik MS, Al-Kali A, et al. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo clinic experience. Haematologica. 2022;107(10):2474.","journal-title":"Haematologica"},{"key":"744_CR72","doi-asserted-by":"crossref","unstructured":"Graham SR. Treatment of extramedullary myeloid sarcoma with radiotherapy. Cureus. 2021;13(6).","DOI":"10.7759\/cureus.15676"},{"issue":"4","key":"744_CR73","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/bloodadvances.2024013826","volume":"9","author":"W-Y Jen","year":"2025","unstructured":"Jen W-Y, Sasaki K, Ravandi F, Kadia TM, Wang SA, Wang W, et al. Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Adv. 2025;9(4):783\u201392.","journal-title":"Blood Adv"},{"key":"744_CR74","doi-asserted-by":"publisher","first-page":"204062072513469","DOI":"10.1177\/20406207251346914","volume":"16","author":"Q Fang","year":"2025","unstructured":"Fang Q, Fung CY, Wang J, Lai WH, Wong RS, Kho BC, et al. Hypomethylating agent versus venetoclax combination: an electronic health records-based target trial emulation among Asian elderly patients with newly diagnosed acute myeloid leukaemia in Hong Kong. Therapeutic Adv Hematol. 2025;16:20406207251346914.","journal-title":"Therapeutic Adv Hematol"},{"key":"744_CR75","doi-asserted-by":"crossref","unstructured":"Krayem B, Frisch A, Horowitz N. Novel therapies for acute myeloid leukemia. Does age still matter? Blood Rev. 2025:101317.","DOI":"10.1016\/j.blre.2025.101317"},{"issue":"19","key":"744_CR76","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMx220003","volume":"386","author":"Gilteritinib or Chemotherapy for","year":"2022","unstructured":"Gilteritinib or Chemotherapy for. Relapsed or refractory FLT3-Mutated AML. N Engl J Med. 2022;386(19):1868.","journal-title":"N Engl J Med"},{"issue":"1","key":"744_CR77","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-024-01617-7","volume":"17","author":"J Cortes","year":"2024","unstructured":"Cortes J. Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML. J Hematol Oncol. 2024;17(1):111.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"744_CR78","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"744_CR79","doi-asserted-by":"crossref","unstructured":"Lloret-Madrid P, Chor\u00e3o P, Guerreiro M, Montesinos P. CAR-T cell therapy for acute myeloid leukemia: where do we stand now? Curr Oncol. 2025;32(6).","DOI":"10.3390\/curroncol32060322"},{"issue":"11","key":"744_CR80","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","volume":"145","author":"S Haubner","year":"2025","unstructured":"Haubner S, Subklewe M, Sadelain M. Honing CAR T cells to tackle acute myeloid leukemia. Blood. 2025;145(11):1113\u201325.","journal-title":"Blood"},{"key":"744_CR81","doi-asserted-by":"publisher","first-page":"1572407","DOI":"10.3389\/fimmu.2025.1572407","volume":"16","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wang W, Wang C, Deng J, Hu Y, Mei H, et al. Recent advances of chimeric antigen receptor T-cell therapy for acute myeloid leukemia. Front Immunol. 2025;16:1572407.","journal-title":"Front Immunol"},{"key":"744_CR82","doi-asserted-by":"crossref","unstructured":"Mosna F. The immunotherapy of acute myeloid leukemia: A clinical point of view. Cancers (Basel). 2024;16(13).","DOI":"10.3390\/cancers16132359"},{"issue":"19","key":"744_CR83","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2024026934","volume":"145","author":"A Linder","year":"2025","unstructured":"Linder A, Nixdorf D, Kuhl N, Piseddu I, Xu T, Holtermann AV, et al. STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia. Blood. 2025;145(19):2149\u201360.","journal-title":"Blood"},{"issue":"2","key":"744_CR84","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/10428194.2022.2148212","volume":"64","author":"S Assouline","year":"2023","unstructured":"Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, et al. A randomized phase II\/III study of \u2018novel therapeutics\u2019 versus Azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of Azacitidine and nivolumab to Azacitidine: SWOG S1612. Leuk Lymphoma. 2023;64(2):473\u20137.","journal-title":"Leuk Lymphoma"},{"key":"744_CR85","doi-asserted-by":"crossref","unstructured":"Chatterjee M, Gupta S, Kumar U, Parashar D, Maitra A, Das K. Extracellular vesicles in acute myeloid leukemia: the role in disease pathogenesis, potential biomarker, and application in clinical settings. Crit Rev Oncol\/Hematol. 2025:104743.","DOI":"10.1016\/j.critrevonc.2025.104743"},{"issue":"1","key":"744_CR86","doi-asserted-by":"publisher","first-page":"10878","DOI":"10.1038\/s41467-024-55231-9","volume":"15","author":"D Forte","year":"2024","unstructured":"Forte D, Pellegrino RM, Falvo P, Garcia-Gonzalez P, Alabed HB, Maltoni F, et al. Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia. Nat Commun. 2024;15(1):10878.","journal-title":"Nat Commun"},{"issue":"3","key":"744_CR87","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/HEP.0000000000000934","volume":"81","author":"Y Sun","year":"2025","unstructured":"Sun Y, Li T, Ding L, Wang J, Chen C, Liu T, et al. Platelet-mediated Circulating tumor cell evasion from natural killer cell killing through immune checkpoint CD155-TIGIT. Hepatology. 2025;81(3):791\u2013807.","journal-title":"Hepatology"},{"key":"744_CR88","doi-asserted-by":"publisher","first-page":"1112059","DOI":"10.3389\/fimmu.2023.1112059","volume":"14","author":"SZ D\u2019Silva","year":"2023","unstructured":"D\u2019Silva SZ, Singh M, Pinto AS. NK cell defects: implication in acute myeloid leukemia. Front Immunol. 2023;14:1112059.","journal-title":"Front Immunol"},{"issue":"3","key":"744_CR89","doi-asserted-by":"publisher","first-page":"100015","DOI":"10.1016\/j.bvth.2024.100015","volume":"1","author":"S Escopy","year":"2024","unstructured":"Escopy S, Chaikof EL. Targeting the P-selectin\/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation. Blood Vessels Thromb Hemost. 2024;1(3):100015.","journal-title":"Blood Vessels Thromb Hemost"},{"issue":"15","key":"744_CR90","doi-asserted-by":"publisher","first-page":"7301","DOI":"10.3390\/ijms26157301","volume":"26","author":"A Agafonova","year":"2025","unstructured":"Agafonova A, Prinzi C, Salinaro AT, Ledda C, Cosentino A, Cambria MT, et al. Breaking barriers: the role of the bone marrow microenvironment in multiple myeloma progression. Int J Mol Sci. 2025;26(15):7301.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"744_CR91","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40364-024-00639-0","volume":"12","author":"T Zhuang","year":"2024","unstructured":"Zhuang T, Wang S, Yu X, He X, Guo H, Ou C. Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment. Biomark Res. 2024;12(1):88.","journal-title":"Biomark Res"},{"key":"744_CR92","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cca.2022.09.015","volume":"536","author":"L Zhang","year":"2022","unstructured":"Zhang L, Liu J, Qin X, Liu W. Platelet\u2013acute leukemia interactions. Clin Chim Acta. 2022;536:29\u201338.","journal-title":"Clin Chim Acta"},{"key":"744_CR93","doi-asserted-by":"publisher","first-page":"640578","DOI":"10.3389\/fimmu.2021.640578","volume":"12","author":"L Schmied","year":"2021","unstructured":"Schmied L, H\u00f6glund P, Meinke S. Platelet-mediated protection of cancer cells from immune surveillance\u2013possible implications for cancer immunotherapy. Front Immunol. 2021;12:640578.","journal-title":"Front Immunol"},{"issue":"1","key":"744_CR94","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s12885-022-09601-5","volume":"22","author":"Y Bi","year":"2022","unstructured":"Bi Y, Wang Z, Feng S, Wang Y, Zhao Y, Li H, et al. Dynamic trajectory of platelet counts after the first cycle of induction chemotherapy in AML patients. BMC Cancer. 2022;22(1):477.","journal-title":"BMC Cancer"},{"key":"744_CR95","doi-asserted-by":"publisher","first-page":"1534158","DOI":"10.3389\/fonc.2025.1534158","volume":"15","author":"C Ling","year":"2025","unstructured":"Ling C, Cao N-N, Niu X-W, Xu S-Y, Gong W-Y, Bao W-Q, et al. Prognostic impact of initial platelet count and post-induction platelet recovery in elderly AML patients: associated with Circulating cytokines. Front Oncol. 2025;15:1534158.","journal-title":"Front Oncol"},{"issue":"4","key":"744_CR96","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/cells9040855","volume":"9","author":"D Stoiber","year":"2020","unstructured":"Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells. 2020;9(4):855.","journal-title":"Cells"},{"key":"744_CR97","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.thromres.2021.12.027","volume":"213","author":"E Yeini","year":"2022","unstructured":"Yeini E, Satchi-Fainaro R. The role of P-selectin in cancer-associated thrombosis and beyond. Thromb Res. 2022;213:S22\u20138.","journal-title":"Thromb Res"},{"key":"744_CR98","doi-asserted-by":"publisher","first-page":"204062072412925","DOI":"10.1177\/20406207241292508","volume":"15","author":"J Kanter","year":"2024","unstructured":"Kanter J, Mennito S, Nair SM, Manwani D, Kutlar A, Shah N, et al. Pharmacokinetics, pharmacodynamics, safety, and efficacy of Crizanlizumab in patients with sickle cell disease: final results from the phase II SOLACE-adults study. Therapeutic Adv Hematol. 2024;15:20406207241292508.","journal-title":"Therapeutic Adv Hematol"},{"issue":"21","key":"744_CR99","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/cells13211778","volume":"13","author":"T-S Lien","year":"2024","unstructured":"Lien T-S, Sun D-S, Chang H-H. Targeted delivery to dying cells through P-Selectin\u2013PSGL-1 axis: A promising strategy for enhanced drug efficacy in liver injury models. Cells. 2024;13(21):1778.","journal-title":"Cells"},{"issue":"108","key":"744_CR100","doi-asserted-by":"publisher","first-page":"eadn4302","DOI":"10.1126\/sciimmunol.adn4302","volume":"10","author":"C Zhong","year":"2025","unstructured":"Zhong C, Wang L, Liu Y, Wang X, Xia Z, Li Y, et al. PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance. Sci Immunol. 2025;10(108):eadn4302.","journal-title":"Sci Immunol"},{"key":"744_CR101","doi-asserted-by":"publisher","first-page":"636238","DOI":"10.3389\/fimmu.2021.636238","volume":"12","author":"JM DeRogatis","year":"2021","unstructured":"DeRogatis JM, Viramontes KM, Neubert EN, Tinoco R. PSGL-1 immune checkpoint Inhibition for CD4\u2009+\u2009T cell cancer immunotherapy. Front Immunol. 2021;12:636238.","journal-title":"Front Immunol"},{"issue":"1","key":"744_CR102","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s40364-024-00700-y","volume":"12","author":"M Yan","year":"2024","unstructured":"Yan M, Wang Z, Qiu Z, Cui Y, Xiang Q. Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy. Biomark Res. 2024;12(1):164.","journal-title":"Biomark Res"},{"issue":"5","key":"744_CR103","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.immuni.2024.04.008","volume":"57","author":"L Nicolai","year":"2024","unstructured":"Nicolai L, Pekayvaz K, Massberg S, Platelets. Orchestrators of immunity in host defense and beyond. Immunity. 2024;57(5):957\u201372.","journal-title":"Immunity"},{"issue":"1","key":"744_CR104","doi-asserted-by":"publisher","first-page":"2499029","DOI":"10.1080\/07853890.2025.2499029","volume":"57","author":"C Lou","year":"2025","unstructured":"Lou C, Cai X. The emerging roles of platelet-derived extracellular vesicles in disease. Ann Med. 2025;57(1):2499029.","journal-title":"Ann Med"},{"issue":"1","key":"744_CR105","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12935-025-03877-w","volume":"25","author":"J Gan","year":"2025","unstructured":"Gan J, Zhang X, Guo J. The role of platelets in tumor immune evasion and metastasis: mechanisms and therapeutic implications. Cancer Cell Int. 2025;25(1):258.","journal-title":"Cancer Cell Int"},{"issue":"5","key":"744_CR106","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1021\/acsbiomaterials.5c00473","volume":"11","author":"HC Yeh","year":"2025","unstructured":"Yeh HC, Gupta K, Lu Y-H, Srinivasan A, Delila L, Yen NTH, et al. Platelet extracellular vesicles as natural delivery vehicles for mitochondrial dysfunction therapy? ACS Biomaterials Sci Eng. 2025;11(5):2601\u201321.","journal-title":"ACS Biomaterials Sci Eng"},{"issue":"39","key":"744_CR107","doi-asserted-by":"publisher","first-page":"26614","DOI":"10.1021\/acsnano.4c04814","volume":"18","author":"Y Li","year":"2024","unstructured":"Li Y, Yu J, Cheng C, Chen W, Lin R, Wang Y, et al. Platelet and erythrocyte membranes coassembled biomimetic nanoparticles for heart failure treatment. ACS Nano. 2024;18(39):26614\u201330.","journal-title":"ACS Nano"},{"key":"744_CR108","doi-asserted-by":"publisher","first-page":"1600227","DOI":"10.3389\/fbioe.2025.1600227","volume":"13","author":"T Chen","year":"2025","unstructured":"Chen T, Chen D, Su W, Liang J, Liu X, Cai M. Extracellular vesicles as vital players in drug delivery: a focus on clinical disease treatment. Front Bioeng Biotechnol. 2025;13:1600227.","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"744_CR109","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3390\/ijms25042071","volume":"25","author":"A Fern\u00e1ndez-Borbolla","year":"2024","unstructured":"Fern\u00e1ndez-Borbolla A, Garc\u00eda-Hevia L, Fanarraga ML. Cell membrane-coated nanoparticles for precision medicine: a comprehensive review of coating techniques for tissue-specific therapeutics. Int J Mol Sci. 2024;25(4):2071.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"744_CR110","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41416-019-0495-5","volume":"121","author":"CR Ireson","year":"2019","unstructured":"Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019;121(2):101\u20138.","journal-title":"Br J Cancer"},{"key":"744_CR111","doi-asserted-by":"crossref","unstructured":"Tang D, Kang R. Platelet activation: a barrier to effective antitumor immunity. Cancer Gene Ther. 2025:1\u20133.","DOI":"10.1038\/s41417-025-00915-7"},{"key":"744_CR112","doi-asserted-by":"crossref","unstructured":"Goel P, Aryal S, Franceski AM, Kuznetsova V, Costa AFDO, Luca F et al. The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF\u03baB signaling. Blood Journal. 2025:blood. 2024028199.","DOI":"10.1182\/blood.2024028199"},{"issue":"1","key":"744_CR113","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1038\/s41598-025-92513-8","volume":"15","author":"A Bertolini","year":"2025","unstructured":"Bertolini A, Picone F, Ferrara I, Della Corte AM, Serio B, Gorrese M, et al. Immature forms of low density granulocytes are increased in acute myeloid leukemia and myelodysplastic syndromes. Sci Rep. 2025;15(1):8661.","journal-title":"Sci Rep"},{"key":"744_CR114","doi-asserted-by":"publisher","first-page":"1558496","DOI":"10.3389\/fimmu.2025.1558496","volume":"16","author":"F Zhong","year":"2025","unstructured":"Zhong F, Yao F, Wang Z, Liu J, Huang B, Wang X. Integrated multiomics analysis and machine learning refine neutrophil extracellular trap-related molecular subtypes and prognostic models for acute myeloid leukemia. Front Immunol. 2025;16:1558496.","journal-title":"Front Immunol"},{"key":"744_CR115","first-page":"28","volume":"7","author":"Y Liang","year":"2024","unstructured":"Liang Y, Wu G, Tan J, Xiao X, Yang L, Saw PE. Targeting netosis: nature\u2019s alarm system in cancer progression. Cancer Drug Resist. 2024;7:28.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"744_CR116","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1038\/s41598-024-59464-y","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J, Wang H, Ding Y, Jiao X, Zhu J, Zhai Z. NET-related gene signature for predicting AML prognosis. Sci Rep. 2024;14(1):9115.","journal-title":"Sci Rep"},{"key":"744_CR117","doi-asserted-by":"publisher","first-page":"e12949","DOI":"10.1111\/eci.12949","volume":"48","author":"K De Filippo","year":"2018","unstructured":"De Filippo K, Rankin SM. CXCR 4, the master regulator of neutrophil trafficking in homeostasis and disease. Eur J Clin Invest. 2018;48:e12949.","journal-title":"Eur J Clin Invest"},{"issue":"12","key":"744_CR118","doi-asserted-by":"publisher","first-page":"2409895","DOI":"10.1002\/advs.202409895","volume":"12","author":"H Liu","year":"2025","unstructured":"Liu H, Zhang B, Chen H, Wang H, Qin X, Sun C, et al. Targeted delivery of c (RGDfk)-Modified liposomes to bone marrow through in vivo hitchhiking neutrophils for multiple myeloma therapy. Adv Sci. 2025;12(12):2409895.","journal-title":"Adv Sci"},{"issue":"4","key":"744_CR119","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10238-022-00884-3","volume":"23","author":"J Li","year":"2023","unstructured":"Li J, Chen H, Zhao S, Wen D, Bi L. Patient-derived intrafemoral orthotopic xenografts of peripheral blood or bone marrow from acute myeloid and acute lymphoblastic leukemia patients: clinical characterization, methodology, and validation. Clin Exp Med. 2023;23(4):1293\u2013306.","journal-title":"Clin Exp Med"},{"issue":"1","key":"744_CR120","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41368-024-00332-w","volume":"17","author":"Z Wang","year":"2025","unstructured":"Wang Z, Saxena A, Yan W, Uriarte SM, Siqueira R, Li X. The impact of aging on neutrophil functions and the contribution to periodontitis. Int J Oral Sci. 2025;17(1):10.","journal-title":"Int J Oral Sci"},{"issue":"4","key":"744_CR121","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/nrclinonc.2018.20","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, et al. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u2018ALL\u2019. Nat Rev Clin Oncol. 2018;15(4):218.","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"744_CR122","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u201363.","journal-title":"Blood"},{"issue":"1","key":"744_CR123","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36\u201348.","journal-title":"Adv Drug Deliv Rev"},{"issue":"10","key":"744_CR124","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics\u2013developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759\u201380.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"744_CR125","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/pharmaceutics15071881","volume":"15","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhang H, Zhang Q, Tao H. Research progress of neutrophil-mediated drug delivery strategies for inflammation-related disease. Pharmaceutics. 2023;15(7):1881.","journal-title":"Pharmaceutics"},{"issue":"1","key":"744_CR126","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41423-024-01244-9","volume":"22","author":"L Koenderman","year":"2025","unstructured":"Koenderman L, Vrisekoop N. Neutrophils in cancer: from biology to therapy. Cell Mol Immunol. 2025;22(1):4\u201323.","journal-title":"Cell Mol Immunol"},{"issue":"8","key":"744_CR127","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/cells11081310","volume":"11","author":"A Cappenberg","year":"2022","unstructured":"Cappenberg A, Kardell M, Zarbock A. Selectin-mediated signaling\u2014Shedding light on the regulation of integrin activity in neutrophils. Cells. 2022;11(8):1310.","journal-title":"Cells"},{"issue":"1","key":"744_CR128","doi-asserted-by":"publisher","first-page":"2384674","DOI":"10.1080\/2162402X.2024.2384674","volume":"13","author":"JW Kwak","year":"2024","unstructured":"Kwak JW, Nguyen HQ, Camai A, Huffman GM, Mekvanich S, Kenney NN, et al. CXCR1\/2 antagonism inhibits neutrophil function and not recruitment in cancer. Oncoimmunology. 2024;13(1):2384674.","journal-title":"Oncoimmunology"},{"issue":"7989","key":"744_CR129","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","volume":"623","author":"C Guo","year":"2023","unstructured":"Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature. 2023;623(7989):1053\u201361.","journal-title":"Nature"},{"issue":"5","key":"744_CR130","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/carcin\/bgs123","volume":"33","author":"ZG Fridlender","year":"2012","unstructured":"Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012;33(5):949\u201355.","journal-title":"Carcinogenesis"},{"issue":"1","key":"744_CR131","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41389-022-00398-3","volume":"11","author":"H Raskov","year":"2022","unstructured":"Raskov H, Orhan A, Gaggar S, G\u00f6genur I. Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy. Oncogenesis. 2022;11(1):22.","journal-title":"Oncogenesis"},{"key":"744_CR132","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.3389\/fimmu.2019.02144","volume":"10","author":"CEM Aarts","year":"2019","unstructured":"Aarts CEM, Hiemstra IH, Tool ATJ, van den Berg TK, Mul E, van Bruggen R, et al. Neutrophils as suppressors of T cell proliferation: does age matter? Front Immunol. 2019;10:2144.","journal-title":"Front Immunol"},{"key":"744_CR133","doi-asserted-by":"crossref","unstructured":"Yajuk O, Baron M, Toker S, Zelter T, Fainsod-Levi T, Granot Z. The PD-L1\/PD-1 axis blocks neutrophil cytotoxicity in cancer. Cells. 2021;10(6).","DOI":"10.3390\/cells10061510"},{"issue":"5","key":"744_CR134","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.trecan.2024.01.010","volume":"10","author":"L Horvath","year":"2024","unstructured":"Horvath L, Puschmann C, Scheiber A, Martowicz A, Sturm G, Trajanoski Z, et al. Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC. Trends Cancer. 2024;10(5):457\u201374.","journal-title":"Trends Cancer"},{"key":"744_CR135","doi-asserted-by":"publisher","first-page":"115143","DOI":"10.1016\/j.addr.2023.115143","volume":"204","author":"E Udofa","year":"2024","unstructured":"Udofa E, Zhao Z. In situ cellular hitchhiking of nanoparticles for drug delivery. Adv Drug Deliv Rev. 2024;204:115143.","journal-title":"Adv Drug Deliv Rev"},{"issue":"14","key":"744_CR136","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.7150\/thno.88002","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Sun S-K, Liu Y, Zhang Z. Advanced hitchhiking nanomaterials for biomedical applications. Theranostics. 2023;13(14):4781.","journal-title":"Theranostics"},{"issue":"1","key":"744_CR137","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/MOH.0000000000000297","volume":"24","author":"S Pitchford","year":"2017","unstructured":"Pitchford S, Pan D, Welch HC. Platelets in neutrophil recruitment to sites of inflammation. Curr Opin Hematol. 2017;24(1):23\u201331.","journal-title":"Curr Opin Hematol"},{"key":"744_CR138","doi-asserted-by":"publisher","first-page":"824112","DOI":"10.3389\/fcvm.2021.824112","volume":"8","author":"R Kaiser","year":"2022","unstructured":"Kaiser R, Escaig R, Erber J, Nicolai L. Neutrophil-platelet interactions as novel treatment targets in cardiovascular disease. Front Cardiovasc Med. 2022;8:824112.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"744_CR139","doi-asserted-by":"publisher","first-page":"10747","DOI":"10.1038\/s41467-024-54817-7","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu Y, Park J, Le QV, Byun J, Choi J, Xu E, et al. NET formation-mediated in situ protein delivery to the inflamed central nervous system. Nat Commun. 2024;15(1):10747.","journal-title":"Nat Commun"},{"issue":"12","key":"744_CR140","doi-asserted-by":"publisher","first-page":"11800","DOI":"10.1021\/acsnano.5b05583","volume":"9","author":"D Chu","year":"2015","unstructured":"Chu D, Gao J, Wang Z. Neutrophil-Mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection. ACS Nano. 2015;9(12):11800\u201311.","journal-title":"ACS Nano"},{"issue":"6","key":"744_CR141","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1021\/acs.nanolett.1c00168","volume":"21","author":"B Li","year":"2021","unstructured":"Li B, Chu T, Wei J, Zhang Y, Qi F, Lu Z, et al. Platelet-Membrane-Coated nanoparticles enable vascular disrupting agent combining Anti-Angiogenic drug for improved tumor vessel impairment. Nano Lett. 2021;21(6):2588\u201395.","journal-title":"Nano Lett"},{"key":"744_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2022.01.004","volume":"172","author":"H Han","year":"2022","unstructured":"Han H, B\u00e1rtolo R, Li J, Shahbazi MA, Santos HA. Biomimetic platelet membrane-coated nanoparticles for targeted therapy. Eur J Pharm Biopharm. 2022;172:1\u201315.","journal-title":"Eur J Pharm Biopharm"},{"key":"744_CR143","doi-asserted-by":"publisher","first-page":"102259","DOI":"10.1016\/j.apmt.2024.102259","volume":"38","author":"Q Liu","year":"2024","unstructured":"Liu Q, Li X, Wang Y, Liu X, Cao Y, Zhang H, et al. Neutrophil hitchhiking for nanoparticle delivery to the central nervous system. Appl Mater Today. 2024;38:102259.","journal-title":"Appl Mater Today"},{"issue":"21","key":"744_CR144","doi-asserted-by":"publisher","first-page":"2504672","DOI":"10.1002\/advs.202504672","volume":"12","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Wang X, Zhang D, Cui H, Tian X, Du W, et al. Precision-Guided stealth missiles in biomedicine: biological Carrier\u2010Mediated nanomedicine hitchhiking strategy. Adv Sci. 2025;12(21):2504672.","journal-title":"Adv Sci"},{"issue":"Suppl 2","key":"744_CR145","doi-asserted-by":"publisher","first-page":"e12949","DOI":"10.1111\/eci.12949","volume":"48","author":"K De Filippo","year":"2018","unstructured":"De Filippo K, Rankin SM. CXCR4, the master regulator of neutrophil trafficking in homeostasis and disease. Eur J Clin Invest. 2018;48(Suppl 2):e12949.","journal-title":"Eur J Clin Invest"},{"key":"744_CR146","doi-asserted-by":"crossref","unstructured":"Wang S, Duan Y, Zhang Q, Komarla A, Gong H, Gao W et al. Drug targeting via platelet Membrane-Coated nanoparticles. Small Struct. 2020;1(1).","DOI":"10.1002\/sstr.202000018"},{"key":"744_CR147","doi-asserted-by":"crossref","unstructured":"Bumbea H, Vladareanu AM, Dumitru I, Popov VM, Ciufu C, Nicolescu A et al. Platelet defects in acute myeloid Leukemia-Potential for hemorrhagic events. J Clin Med. 2021;11(1).","DOI":"10.3390\/jcm11010118"},{"key":"744_CR148","doi-asserted-by":"publisher","first-page":"910908","DOI":"10.3389\/fcimb.2022.910908","volume":"12","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Xu Z, Liu Z. Impact of neutrophil extracellular traps on thrombosis formation: new findings and future perspective. Front Cell Infect Microbiol. 2022;12:910908.","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"744_CR149","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/pharmaceutics16040531","volume":"16","author":"S Zhang","year":"2024","unstructured":"Zhang S, Zhang X, Gao H, Zhang X, Sun L, Huang Y, et al. Cell membrane-coated biomimetic nanoparticles in cancer treatment. Pharmaceutics. 2024;16(4):531.","journal-title":"Pharmaceutics"},{"key":"744_CR150","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jconrel.2024.07.013","volume":"373","author":"A Safdar","year":"2024","unstructured":"Safdar A, Wang P, Muhaymin A, Nie G, Li S. From bench to bedside: platelet biomimetic nanoparticles as a promising carriers for personalized drug delivery. J Controlled Release. 2024;373:128\u201344.","journal-title":"J Controlled Release"},{"issue":"1","key":"744_CR151","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12951-025-03262-9","volume":"23","author":"H Chu","year":"2025","unstructured":"Chu H, Xu Y, Shan Y, Sun M, Zhao W, Fang X, et al. Platelet hitchhiking vascular-disrupting agents for self-amplified tumor-targeting therapy. J Nanobiotechnol. 2025;23(1):197.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"744_CR152","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","volume":"14","author":"Y Chang","year":"2023","unstructured":"Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14(1):2266.","journal-title":"Nat Commun"},{"issue":"7","key":"744_CR153","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/cancers17071232","volume":"17","author":"H Wahnou","year":"2025","unstructured":"Wahnou H, El Kebbaj R, Hba S, Ouadghiri Z, El Faqer O, Pinon A, et al. Neutrophils and neutrophil-based drug delivery systems in anti-cancer therapy. Cancers. 2025;17(7):1232.","journal-title":"Cancers"},{"key":"744_CR154","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jconrel.2024.01.068","volume":"367","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Li M, Guo Y, Jin J, Pei F, Wang W, et al. Neutrophil hitchhiking nanoparticles enhance bacteria-mediated cancer therapy via NETosis reprogramming. J Controlled Release. 2024;367:661\u201375.","journal-title":"J Controlled Release"},{"issue":"1","key":"744_CR155","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-025-00676-x","volume":"14","author":"C Cai","year":"2025","unstructured":"Cai C, Liu Y, Lu R, Fan X, Zeng S, Gan P. Platelets in cancer and immunotherapy: functional dynamics and therapeutic opportunities. Experimental Hematol Oncol. 2025;14(1):83.","journal-title":"Experimental Hematol Oncol"},{"issue":"1","key":"744_CR156","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-025-00656-1","volume":"14","author":"J Venturini","year":"2025","unstructured":"Venturini J, Chakraborty A, Baysal MA, Tsimberidou AM. Developments in nanotechnology approaches for the treatment of solid tumors. Experimental Hematol Oncol. 2025;14(1):76.","journal-title":"Experimental Hematol Oncol"},{"key":"744_CR157","doi-asserted-by":"crossref","unstructured":"Zhao X, Huang H, Liu M, Wang P, Song S, Cheng Z et al. In vivo neutrophils hitchhiking for tumor targeting and microenvironment regulation boosts oncolytic virus therapy. Cell Rep Med. 2025.","DOI":"10.1016\/j.xcrm.2025.102314"},{"issue":"5","key":"744_CR158","doi-asserted-by":"publisher","first-page":"e70647","DOI":"10.1002\/hsr2.70647","volume":"8","author":"NT Fard","year":"2025","unstructured":"Fard NT, Khademi M, Salahi-Niri A, Esmaeili S. Nanotechnology in hematology: enhancing therapeutic efficacy with nanoparticles. Health Sci Rep. 2025;8(5):e70647.","journal-title":"Health Sci Rep"},{"issue":"1","key":"744_CR159","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","volume":"9","author":"B Wang","year":"2024","unstructured":"Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Therapy. 2024;9(1):200.","journal-title":"Signal Transduct Target Therapy"},{"key":"744_CR160","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jconrel.2025.01.053","volume":"379","author":"S Chen","year":"2025","unstructured":"Chen S, Wu A, Shen X, Kong J, Huang Y. Disrupting the dangerous alliance: dual anti-inflammatory and anticoagulant strategy targets platelet-neutrophil crosstalk in sepsis. J Controlled Release. 2025;379:814\u201331.","journal-title":"J Controlled Release"},{"issue":"1","key":"744_CR161","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/jfb16010015","volume":"16","author":"L Xie","year":"2025","unstructured":"Xie L, Gan F, Hu Y, Zheng Y, Lan J, Liu Y, et al. From blood to therapy: the revolutionary application of platelets in cancer-targeted drug delivery. J Funct Biomaterials. 2025;16(1):15.","journal-title":"J Funct Biomaterials"},{"issue":"19","key":"744_CR162","doi-asserted-by":"publisher","first-page":"2310318","DOI":"10.1002\/adma.202310318","volume":"36","author":"J Zhang","year":"2024","unstructured":"Zhang J, Gu J, Wang X, Ji C, Yu D, Wang M, et al. Engineering and targeting neutrophils for cancer therapy. Adv Mater. 2024;36(19):2310318.","journal-title":"Adv Mater"},{"issue":"1","key":"744_CR163","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12959-024-00607-6","volume":"22","author":"M Mitrovic","year":"2024","unstructured":"Mitrovic M, Pantic N, Bukumiric Z, Sabljic N, Virijevic M, Pravdic Z, et al. Venous thromboembolism in patients with acute myeloid leukemia: development of a predictive model. Thromb J. 2024;22(1):37.","journal-title":"Thromb J"},{"issue":"6","key":"744_CR164","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11864-023-01089-w","volume":"24","author":"M Olivi","year":"2023","unstructured":"Olivi M, Di Biase F, Lanzarone G, Arrigo G, Martella F, Apolito V, et al. Thrombosis in acute myeloid leukemia: Pathogenesis, risk factors and therapeutic challenges. Curr Treat Options Oncol. 2023;24(6):693\u2013710.","journal-title":"Curr Treat Options Oncol"},{"key":"744_CR165","doi-asserted-by":"crossref","unstructured":"Li H, Shan W, Zhao X, Sun W. Neutrophils: linking inflammation to thrombosis and unlocking new treatment horizons. Int J Mol Sci [Internet]. 2025; 26(5).","DOI":"10.3390\/ijms26051965"},{"issue":"8","key":"744_CR166","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12032-025-02860-9","volume":"42","author":"S Amirlatifi","year":"2025","unstructured":"Amirlatifi S, Forouzin S, Sadati E, Moradpanah S, Fazeli R, Panahinia P, et al. Ovarian cancer, neutrophil hitchhiking, and nets: unraveling their role in pathogenesis and management. Med Oncol. 2025;42(8):302.","journal-title":"Med Oncol"},{"issue":"1","key":"744_CR167","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-020-00342-0","volume":"5","author":"X Fu","year":"2020","unstructured":"Fu X, Shi Y, Qi T, Qiu S, Huang Y, Zhao X, et al. Precise design strategies of nanomedicine for improving cancer therapeutic efficacy using subcellular targeting. Signal Transduct Target Therapy. 2020;5(1):262.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"744_CR168","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1021\/acsami.3c13948","volume":"16","author":"P Grav\u00e1n","year":"2024","unstructured":"Grav\u00e1n P, Pe\u00f1a-Mart\u00edn J, de Andr\u00e9s JL, Pedrosa M, Villegas-Montoya M, Galisteo-Gonz\u00e1lez F, et al. Exploring the impact of nanoparticle stealth coatings in cancer models: from pegylation to cell Membrane-Coating nanotechnology. ACS Appl Mater Interfaces. 2024;16(2):2058\u201374.","journal-title":"ACS Appl Mater Interfaces"},{"key":"744_CR169","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jconrel.2025.01.066","volume":"379","author":"SL Cheng","year":"2025","unstructured":"Cheng SL, Wu CH, Tsai YJ, Song JS, Chen HM, Yeh TK, et al. CXCR4 antagonist-loaded nanoparticles reprogram the tumor microenvironment and enhance immunotherapy in hepatocellular carcinoma. J Control Release. 2025;379:967\u201381.","journal-title":"J Control Release"},{"issue":"3","key":"744_CR170","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41563-023-01481-9","volume":"22","author":"DE Tylawsky","year":"2023","unstructured":"Tylawsky DE, Kiguchi H, Vaynshteyn J, Gerwin J, Shah J, Islam T, et al. P-selectin-targeted nanocarriers induce active crossing of the blood\u2013brain barrier via caveolin-1-dependent transcytosis. Nat Mater. 2023;22(3):391\u20139.","journal-title":"Nat Mater"},{"issue":"42","key":"744_CR171","doi-asserted-by":"publisher","first-page":"28866","DOI":"10.1021\/acsnano.4c09054","volume":"18","author":"R Mathur","year":"2024","unstructured":"Mathur R, Elsafy S, Press AT, Br\u00fcck J, Hornef M, Martin L, et al. Neutrophil hitchhiking enhances liposomal dexamethasone therapy of sepsis. ACS Nano. 2024;18(42):28866\u201380.","journal-title":"ACS Nano"},{"issue":"14","key":"744_CR172","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2024028199","volume":"146","author":"P Goel","year":"2025","unstructured":"Goel P, Aryal S, Franceski AM, Kuznetsova V, Costa A, Luca F, et al. The acute myeloid leukemia microenvironment impairs neutrophil maturation and function through NF-\u03baB signaling. Blood. 2025;146(14):1707\u201321.","journal-title":"Blood"},{"key":"744_CR173","doi-asserted-by":"crossref","unstructured":"Ostafin M, Ciepiela O, Pruchniak M, Wachowska M, Uli\u0144ska E, Mr\u00f3wka P et al. Dynamic changes in the ability to release neutrophil extracellular traps in the course of childhood acute leukemias. Int J Mol Sci. 2021;22(2).","DOI":"10.3390\/ijms22020821"},{"key":"744_CR174","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fmed.2019.00021","volume":"6","author":"MA Torres-Acosta","year":"2019","unstructured":"Torres-Acosta MA, Harrison RP, Csaszar E, Rito-Palomares M, Brunck MEG. Ex vivo manufactured neutrophils for treatment of Neutropenia-A process economic evaluation. Front Med (Lausanne). 2019;6:21.","journal-title":"Front Med (Lausanne)"},{"key":"744_CR175","doi-asserted-by":"publisher","first-page":"820058","DOI":"10.3389\/fimmu.2022.820058","volume":"13","author":"M Blanter","year":"2022","unstructured":"Blanter M, Cambier S, De Bondt M, Vanbrabant L, P\u00f6rtner N, Abouelasrar Salama S, et al. Method matters: effect of purification technology on neutrophil phenotype and function. Front Immunol. 2022;13:820058.","journal-title":"Front Immunol"},{"issue":"9","key":"744_CR176","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","volume":"24","author":"M Qayed","year":"2022","unstructured":"Qayed M, McGuirk JP, Myers GD, Parameswaran V, Waller EK, Holman P, et al. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy. 2022;24(9):869\u201378.","journal-title":"Cytotherapy"},{"issue":"1","key":"744_CR177","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s13054-018-2114-x","volume":"22","author":"C Aubron","year":"2018","unstructured":"Aubron C, Flint AWJ, Ozier Y, McQuilten Z. Platelet storage duration and its clinical and transfusion outcomes: a systematic review. Crit Care. 2018;22(1):185.","journal-title":"Crit Care"},{"issue":"7","key":"744_CR178","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3324\/haematol.12489","volume":"93","author":"A Drewniak","year":"2008","unstructured":"Drewniak A, Boelens JJ, Vrielink H, Tool AT, Bruin MC, van den Heuvel-Eibrink M, et al. Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. Haematologica. 2008;93(7):1058\u201367.","journal-title":"Haematologica"},{"issue":"2","key":"744_CR179","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jim.2008.09.003","volume":"339","author":"A Avenda\u00f1o","year":"2008","unstructured":"Avenda\u00f1o A, Sales-Pardo I, Marin L, Marin P, Petriz J. Oxidative burst assessment and neutrophil-platelet complexes in unlysed whole blood. J Immunol Methods. 2008;339(2):124\u201331.","journal-title":"J Immunol Methods"},{"issue":"1\u20132","key":"744_CR180","doi-asserted-by":"publisher","first-page":"e24994","DOI":"10.1002\/jcla.24994","volume":"38","author":"C Liu","year":"2024","unstructured":"Liu C, Su Y, Guo W, Ma X, Qiao R. The platelet storage lesion, what are we working for? J Clin Lab Anal. 2024;38(1\u20132):e24994.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"744_CR181","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s13346-022-01252-0","volume":"13","author":"H Liu","year":"2023","unstructured":"Liu H, Su YY, Jiang XC, Gao JQ. Cell membrane-coated nanoparticles: a novel multifunctional biomimetic drug delivery system. Drug Deliv Transl Res. 2023;13(3):716\u201337.","journal-title":"Drug Deliv Transl Res"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00744-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00744-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00744-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:04:09Z","timestamp":1769684649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00744-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":181,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00744-w","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}